Evidence map›Paper›PMID 40731182›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Human amylin is a potent antimicrobial peptide that exhibits antimicrobial synergism with the amyloid beta protein.

Deepak K Vijaya Kumar, Teryn A Mitchell, Breeya A Tailor, Alexander P Moir, Nanda K Navalpur Shanmugam, William A Eimer, Jessica Ghelichi, Se Hoon Choi, Chienwen Su, Alex S Rodriguez and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. β-Amyloid (Aβ) and Human Cathelicidin LL-37: Two Sides of the Same Coin?International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Deepak K Vijaya KumarGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Teryn A MitchellGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Breeya A TailorGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Alexander P MoirGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Nanda K Navalpur ShanmugamGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
William A EimerGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Jessica GhelichiGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Se Hoon ChoiGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Chienwen SuMucosal Immunology and Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Alex S RodriguezGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Eunhee KimGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Robert D MoirGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Rudolph E TanziGenetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

Funding

Cure Alzheimer's Fund 238023Dake Family FoundationNIH HHS 1S10RR023594S10
6 · The paper itself

Abstract

introductionOur previous studies demonstrated the antimicrobial properties of amyloid beta (Aβ) of Alzheimer's disease (AD) against clinically relevant bacteria, yeast, and viruses. In this study, we investigate the antimicrobial function of the 37-amino acid amylin of type 2 diabetes (T2D), expanding on its potential involvement in AD.

methodsWe used in vitro assays, including human three-dimensional neuronal cell culture models, to test microbicidal, microbiostatic, and synergistic antimicrobial interactions between amylin and Aβ against microbes.

resultsOur results confirm that amylin is a broad-spectrum antimicrobial peptide that exhibits both microbicidal and microbiostatic mechanisms. We also identified a synergistic antimicrobial effect between amylin and Aβ in inhibiting Salmonella Typhimurium and Staphylococcus aureus. DISCUSSION: The findings show that amylin is an antimicrobial peptide and functions synergistically with Aβ against bacterial pathogens. Increased amylin secretion after bacterial infection suggests a broader biological role for amylin beyond its involvement in T2D. HIGHLIGHTS: Amylin is a potent antimicrobial peptide, eliminating ≥99.9% bacteria at low doses. Amylin efficiently traps and neutralizes microbes via a fibril-driven mechanism. Amylin protects human cells and Caenorhabditis elegans from Salmonella or Candida infection. Synthetic amylin and amyloid beta (Aβ) together amplify antibacterial response against bacteria. Synergy between cell-derived amylin and Aβ drives dynamic antimicrobial activity against neural infection.

Indexed as

Amyloid beta-PeptidesAnti-Infective AgentsAntimicrobial PeptidesIslet Amyloid PolypeptideAnimalsDrug SynergismHumansNeuronsSalmonella typhimuriumStaphylococcus aureusAmyloid beta-PeptidesAnti-Infective AgentsAntimicrobial PeptidesIslet Amyloid PolypeptideAlzheimer's diseaseamylinamyloid betaantimicrobialsbacteriadiabetesfungihostimmunityinfection

Identifiers

PMID40731182
PMCPMC12307129

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.